Page 49 - GALENIKA MEDICAL JOURNAL

40. Sun Y, Yu X, Liu J, Zhou N, Chen L, Zhao Y, et al. Effect of bedtime 48. Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al.
administration of blood-pressure lowering agents on ambulatory blood Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose
pressure monitoring results: A meta-analysis. Cardiol J. 2016;23(4):473- Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled
81. Nocturnal Hypertension: Results From the Randomized, Placebo-
Controlled SACRA Study. Circulation. 2019 Apr 30;139(18):2089-97.
41. Hermida RC, Crespo JJ, Domínguez-Sardiña M, Otero A, Moyá A, Ríos
MT, et al. Hygia Project Investigators. Bedtime hypertension treatment 49. Fava C, Dorigoni S, Dalle Vedove F, Danese E, Montagnana M, Guidi GC,
improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. et al. Effect of CPAP on blood pressure in patients with OSA/hypopnea a
Eur Heart J. 2020 Dec 21;41(48):4565-76. systematic review and meta-analysis. Chest. 2014 Apr;145(4):762-71.
42. Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb 50. Kario K, Bhatt DL, Kandzari DE, Brar S, Flack JM, Gilbert C, et al. Impact
DJ, et al. TIME Study Group. Cardiovascular outcomes in adults of Renal Denervation on Patients With Obstructive Sleep Apneja and
with hypertension with evening versus morning dosing of usual Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial. Circ
antihypertensives in the UK (TIME study): a prospective, randomised, J. 2016 May 25;80(6):1404-12.
open-label, blinded-endpoint clinical trial. Lancet. 2022 Oct
22;400(10361):1417-25. 51. Lee EK, Poon P, Yu CP, Lee VW, Chung VC, Wong SY. Controlled-release
oral melatonin supplementation for hypertension and nocturnal
43. Kario K, Tomitani N, Kanegae H, Ishii H, Uchiyama K, Yamagiwa K, et hypertension: A systematic review and meta-analysis. J Clin Hypertens
al. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/ (Greenwich). 2022 May;24(5):529-35.
Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled
Nocturnal Hypertension Evaluated by Information and Communication
Technology-Based Nocturnal Home Blood Pressure Monitoring - The
NOCTURNE Study. Circ J. 2017 Jun 23;81(7):948-57. Konflikt interesa: Nema
44. Hoshino A, Nakamura T, Matsubara H. The bedtime administration Primljeno: 21. 02. 2024.
ameliorates blood pressure variability and reduces urinary albumin Prihvaćeno: 04. 03. 2024.
excretion in amlodipine-olmesartan combination therapy. Clin Exp
Hypertens. 2010;32(7):416-22. Onlajn: 31. 03. 2024.
45. Giles TD, Alessi T, Purkayastha D, Zappe D. Comparative efficacy of
aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper
hypertensive patients: a pooled analysis. J Clin Hypertens (Greenwich).
2012 May;14(5):299-306.
46. Kario K, Nariyama J, Kido H, Ando S, Takiuchi S, Eguchi K, et al. Effect
of a novel calcium channel blocker on abnormal nocturnal blood
pressure in hypertensive patients. J Clin Hypertens (Greenwich). 2013
Jul;15(7):465-72.
47. Yasuda G, Hasegawa K, Kuji T, Ogawa N, Shimura G, Umemura S, et al.
Effects of doxazosin on ambulatory blood pressure and sympathetic
nervous activity in hypertensive Type 2 diabetic patients with overt
nephropathy. Diabet Med. 2005 Oct;22(10):1394-400.

REVIJALNI RADOVI Galenika Medical Journal, 2024; 3(9):41-47. 47